Postdose 3 G1 serum neutralizing antibody as correlate of protection for pentavalent rotavirus vaccine
Authors:
Open Access
- 24 August 2017
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 13 (10) , 2357-2363
Abstract
Although clinical trials of the pentavalent rotavirus vaccine (RotaTeq®, RV5) have demonstrated efficacy against RV gastroenteritis (RGE) in low and high-income settings, a clear correlate of protection or a measure of immune response that could predict efficacy has yet to be identified. This is the first time that immunogenicity data with both serum neutralized antibody (SNA) titers and anti-RV IgA titers from several clinical efficacy trials were pooled to provide a unique context for evaluating the correlation between immunogenicity and RGE risk or efficacy of RV5. The correlation between immunogenicity and RGE risk is evaluated with data at the individual subject level. The analyses show that higher Postdose 3 (PD3) G1 SNA titers are associated with lower odds of contracting any RGE. The correlation between immunogenicity and efficacy is assessed using aggregated population level data, which shows higher efficacy associated with higher PD3 G1 SNA geometric mean titer (GMT) ratio (between RV5 and placebo) and PD3 serum anti-RV IgA GMT ratio. Among high-income countries, efficacy plateaus over the range of PD3 G1 SNA GMT ratios and PD3 serum anti-RV IgA GMT ratios. From both individual- and population-level analyses, PD3 G1 SNA titers correlated most closely with the RGE risk or efficacy for RV5.Keywords
This publication has 29 references indexed in Scilit:
- Nomenclature for Immune Correlates of Protection After VaccinationClinical Infectious Diseases, 2012
- Immune Responses to Rotavirus Infection and Vaccination and Associated Correlates of ProtectionThe Journal of Infectious Diseases, 2010
- Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trialThe Lancet, 2010
- Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trialThe Lancet, 2010
- Global Mortality Associated with Rotavirus Disease among Children in 2004The Journal of Infectious Diseases, 2009
- Concomitant Use of the Oral Pentavalent Human-Bovine Reassortant Rotavirus Vaccine and Oral Poliovirus VaccineThe Pediatric Infectious Disease Journal, 2008
- Efficacy, Immunogenicity, and Safety of a Pentavalent Human-Bovine (WC3) Reassortant Rotavirus Vaccine at the End of Shelf LifePediatrics, 2007
- Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infantsVaccine, 2006
- Serologic Correlates of Immunity in a Tetravalent Reassortant Rotavirus Vaccine TrialThe Journal of Infectious Diseases, 1997
- Protective effect of preexisting rotavirus‐specific immunoglobulin A against naturally acquired rotavirus infection in childrenJournal of Medical Virology, 1987